Completed PHASE1 INTERVENTIONAL 7-arm NCT06082596

Study of BEBT-908 in Subjects With Advanced Hematological Tumors

A Multicenter, Open, Phase I Clinical Study of BEBT-908 for Injection in the Treatment of Relapsed Refractory Malignant Lymphoma, Multiple Myeloma and Chronic Lymphoblastic Leukemia

Sponsor: BeBetter Med Inc

Conditions Relapsed or Refractory Multiple Myeloma Relapsed or Refractory Non-Hodgkin's Lymphoma

Interventions BEBT-908 for injection

Updated 3 times since 2023 Last updated: Oct 9, 2023 Started: Mar 2, 2016 Primary completion: Mar 8, 2019 Completion: Mar 8, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Relapsed or Refractory Multiple Myeloma and Relapsed or Refractory Non-Hodgkin's Lymphoma and is currently completed. BeBetter Med Inc leads this study, which shows 3 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Nov 2023 — Jul 2024 [monthly]

Completed PHASE1

First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BeBetter Med Inc

Data source: BeBetter Med Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Changsha, China